Cg01-Gbm Standard Chemotherapy Versus Chemotherapy Chosen By Cancer Stem Cell Chemosensitivity Testing In The Management Of Patients With Recurrent Glioblastoma Multiforme (Gbm).
Posted Date: Jun 10, 2019
- Investigator: Nicholas Marko
- Specialties: Cancer, Oncology
- Type of Study: Observational/Survey
To evaluate median overall survival in recurrent glioblastoma multiforme patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician
To Be Eligible You Must Be At Least 18 Years Old, Have A Recurrent Surgically Resectable Tumor, Survival Expentency Of Over 3 Months, Nonpregnant And Nonnursing.
For More Information:
Uc Cancer Institute